Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Enteric Nervous System: Regulation of GI Motor Activity01:11

Enteric Nervous System: Regulation of GI Motor Activity

The Enteric Nervous System (ENS) plays a pivotal role in regulating gastrointestinal or GI motor activity. This complex network of nerves, deeply embedded within the gut wall, responds to changes in the gut environment and receives input from both the autonomic nervous system and the central nervous system. By doing so, the ENS operates various programs tailored to the body's nutritional status and needs.
During periods of fasting, the ENS initiates the migrating myoelectric complex, a program...
Gastrointestinal Motility Disorders01:20

Gastrointestinal Motility Disorders

Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives01:22

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This makes...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term efficacy and safety of sacral neuromodulation for diarrhoea-predominant and mixed irritable bowel syndrome.

Techniques in coloproctology·2025
Same author

Treatment of patients with screen-detected colorectal cancer is less strenuous: a nationwide cohort study with long-term follow-up.

Public health·2024
Same author

Effects of phenylephrine on systemic and cerebral circulations in humans: a systematic review with mechanistic explanations.

Anaesthesia·2023
Same author

Drug survival of biologic therapies for palmoplantar pustulosis: A nationwide study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

The gold standard program (GSP) for smoking cessation: a cohort study of its effectiveness among smokers with and without cancer.

Acta oncologica (Stockholm, Sweden)·2023
Same author

Method for quantification of porcine type I interferon activity using luminescence, by direct and indirect means.

BMC biotechnology·2022
Same journal

Effect of Endoscopic Retrograde Appendicitis Therapy on Postoperative Gastrointestinal Function in Patients With Chronic Fecalith Appendicitis.

Gastroenterology research and practice·2026
Same journal

Divergent Trajectories of the Burden of MASLD Attributable to High Fasting Plasma Glucose in China and Globally: A GBD Study 1990-2021 and Projections to 2046.

Gastroenterology research and practice·2026
Same journal

From "Monarch, Minister, Assistant, and Envoy" to "Microbial Dialogue": A Review of Novel Mechanisms by Which Chinese Herb Pairs Improve Metabolic Diseases Through Gut Microbiota Metabolic Regulation.

Gastroenterology research and practice·2026
Same journal

Effects of Aging on Correlation of Striated Esophageal and Pharyngeal Deglutitive Motor Function.

Gastroenterology research and practice·2026
Same journal

RETRACTION: "Influence of Rosiglitazone on the Expression of PPAR<i>γ</i>, NF-<i>κ</i>B,and TNF-<i>α</i> in Rat Model of Ulcerative Colitis".

Gastroenterology research and practice·2026
Same journal

High Prevalence of Sarcopenia in Noncirrhotic Women With Primary Biliary Cholangitis: A Comparative Study of Clinical Characteristics and Risk Factors.

Gastroenterology research and practice·2026
See all related articles

Related Experiment Video

Updated: May 12, 2026

Autonomous and Rechargeable Microneurostimulator Endoscopically Implantable into the Submucosa
08:17

Autonomous and Rechargeable Microneurostimulator Endoscopically Implantable into the Submucosa

Published on: September 27, 2018

Neurostimulation for neurogenic bowel dysfunction.

J Worsøe1, M Rasmussen, P Christensen

  • 1Department of Surgery P, Aarhus University Hospital, Tage-Hansen Gade, 8000 Aarhus, Denmark.

Gastroenterology Research and Practice
|April 11, 2013
PubMed
Summary
This summary is machine-generated.

Neurostimulation offers potential treatments for neurogenic bowel dysfunction (NBD), including sacral nerve stimulation and nerve re-routing. Further controlled trials are needed to establish efficacy and guide widespread clinical use for NBD management.

More Related Videos

Breathing-controlled Electrical Stimulation (BreEStim) for Management of Neuropathic Pain and Spasticity
11:34

Breathing-controlled Electrical Stimulation (BreEStim) for Management of Neuropathic Pain and Spasticity

Published on: January 10, 2013

Related Experiment Videos

Last Updated: May 12, 2026

Autonomous and Rechargeable Microneurostimulator Endoscopically Implantable into the Submucosa
08:17

Autonomous and Rechargeable Microneurostimulator Endoscopically Implantable into the Submucosa

Published on: September 27, 2018

Breathing-controlled Electrical Stimulation (BreEStim) for Management of Neuropathic Pain and Spasticity
11:34

Breathing-controlled Electrical Stimulation (BreEStim) for Management of Neuropathic Pain and Spasticity

Published on: January 10, 2013

Area of Science:

  • Neuroscience
  • Gastroenterology
  • Neurology

Background:

  • Neurogenic bowel dysfunction (NBD) is characterized by impaired bowel function due to neurological issues, often leading to fecal incontinence, constipation, and abdominal discomfort.
  • Standard treatments for NBD may fail, necessitating surgical interventions or alternative therapies.
  • Neurostimulation techniques have emerged as potential therapeutic options for NBD, though their efficacy and clinical application remain under investigation.

Purpose of the Study:

  • To systematically review the existing literature on various neurostimulation methods for treating neurogenic bowel dysfunction (NBD).
  • To evaluate the reported outcomes and potential benefits of different neurostimulation techniques in managing NBD.

Main Methods:

  • A comprehensive literature search was conducted across major databases (PubMed, Embase, Scopus, Cochrane Library).
  • The search focused on studies investigating sacral anterior root stimulation (SARS), sacral nerve stimulation (SNS), peripheral nerve stimulation, magnetic stimulation, and nerve re-routing for NBD treatment.

Main Results:

  • Sacral anterior root stimulation (SARS) demonstrated improvements in bowel function for some patients with complete spinal cord injury (SCI).
  • Nerve re-routing showed promise in facilitating defecation via mechanical stimulation in SCI and myelomeningocele patients.
  • Sacral nerve stimulation (SNS) was found to reduce NBD in select patients with incomplete neurological lesions.
  • Non-invasive peripheral electrical or magnetic stimulation may offer alternative treatment options.

Conclusions:

  • Current evidence for neurostimulation in NBD is primarily derived from pilot or retrospective studies.
  • Larger, controlled clinical trials with precise inclusion criteria and defined endpoints are essential.
  • Further research is recommended before widespread adoption of neurostimulation therapies for neurogenic bowel dysfunction.